Rational Pharmacotherapy in Cardiology

Advanced search

The Use of Levosimendan for the Treatment of Heart Failure and its Potential Organoprotective Effects

Full Text:


The review article is aimed at providing a recent update on the use of levosimendan, an inotropic drug in current use for the treatment of heart failure. The review discusses its mechanisms of action, main hemodynamic effects, clinical trials and obtained evidences that have formed the basis of the current guidelines on its use, as well as the latest clinical and experimental trials evaluating its organ-protective effects. Conclusion: levosimendan has a promising potential for treating heart failure, prescribed even in low doses, and may be regarded as a drug with cerebroprotective and possible nephroprotective effects, requiring further large randomized clinical trials.

About the Authors

N. B. Lebedeva
Research Institute for Complex Issues of Cardiovascular Diseases
Russian Federation

Natalia B. Lebedeva


L. Yu. Chesnokova
Research Institute for Complex Issues of Cardiovascular Diseases
Russian Federation

Larisa Yu. Chesnokova



1. Boytsov SA, Shal'nova SA, Deev AD. Mortality from cardiovascular diseases in the Russian Federation and possible mechanisms for its change. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2018;118(8):98-103 (In Russ.) . DOI:10.17116/jnevro201811808198.

2. Yancy CW, Januzzi JL, Allen LA, et al. 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology task force on expert consensus decision pathways. J Am Coll Cardiol. 2018;71(2):201-230. DOI:10.1016/j.jacc.2017.11.025.

3. Mareev VJu, Fomin IV, Ageev FT, et al. Clinical recommendations. Chronic heart failure. Heart Failure Journal. 2017;(1):3-40 (In Russ.) DOI:10.18087/ rhfj.2017.1.2346.

4. Lam CS, Gamble GD, Ling LH, Sim D. Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study. Eur Heart J. 2018;39(20);1770-80. DOI:10.1093/eurheartj/ehy005.

5. Maack C, Eschenhagen T, Hamdani N. Treatments targeting inotropy. Eur Heart J. 2019;40(44):3626-44. DOI:10.1093/eurheartj/ehy600.

6. Kivikko M, Pollesllo P, Tarvasmaki T, et al. Effect of baseline characteristics on mortality in the SURVIVE trial on the effect of levosimendan vs dobutamine in fcute heart failure: Sub-analysis of the Finnish patients. Int J Сardiology. 2016;215:26-31. DOI:10.1016/j.ijcard.2016.04.064.

7. Silvetti S, Nieminen MS. Repeated or intermittent levosimendan treatment in advanced heart failure: An updated meta-analysis. ESC Heart Fail. 2017;4(4):595-604. DOI:10.1016/j.ijcard.2015.08.188.

8. Slawsky MT, Colucci WS, Gottlieb SS, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation. 2000;102(18):2222-7. DOI:10.1161/01.cir.102.18.2222.

9. Ozdem SS, Yalcin O, Meiselman HJ, et al. The role of potassium channels in relaxant effect of levosimendan in rat small mesenteric arteries. Cardiovasc. Drugs Ther. 2006;20(2):123-7. DOI:10.1007/s10557-006-7294-y.

10. Pollesello P, Papp Z. The cardioprotective effects of levosimendan: preclinical and clinical evidence. J Cardiovasc Pharmacol. 2007;50(3):257-63. DOI:10.1097/FJC.0b013e3180986230.

11. Gardner RS, McDonagh TA, Walker LN. Heart failure. London: Oxford University Press; 2014. p.316-327.

12. Robertson IM, Baryshnikova OK, Li MX, Sykes BD. Defining the binding site of levosimendan and its analogues in aregulatory cardiac troponin C-troponin I complex. Biochemistry. 2008;47(28):7485-95. DOI:10.1021/bi800438k.

13. Kivikko ML, Lehtonen L, Colucci WS. Sustained hemodynamic affects of intravenous levosimendan. Circulation. 2003;107(1):81-6. DOI:10.1161/01.CIR.0000043245.00859.11.

14. Bergh CH, Andersson B, Dahlstrom U, et al. Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers. Eur J Heart Fail. 2010;1 (4):404-410. DOI:10.1093/eurjhf/hfq032.

15. Nieminen MS, Akkila J, Hasenfuss G, et al. (2000) Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol. 2000;36(6):1903-12. DOI:10.1016/s0735-1097(00)00961-x.

16. Mebazaa А, Parissis J, Porcher R, et al. Short-term survival by treatment among patients hospitalized with acute heart failure: the global ALARM-HF registry using propensity scoring methods. Intensive Care Med. 2011;37(2):290-301. DOI:10.1007/s00134-010-2073-4.

17. Moiseyev VS, Proder P, Andrejevs N, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J. 2002;23(18):1422-32. DOI:10.1053/euhj.2001.3158.

18. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002;360(9328):196-202. DOI:10.1016/S0140-6736(02)09455-2.

19. Nainggolan L. CASINO results: Should docs gamble on levosimendan? [cited 2020 Jan 10]. Available from:

20. Mebazaa A, Nieminen MS, Filippatos G, et al. Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE. Eur J Heart Fail. 2009;11(3):304-11. DOI:10.1093/eurjhf/hfn045.

21. Packer M, Colucci W, Fisher L, et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. J Am Coll Cardiol. 2013;1(2):103-111. DOI:10.1016/j.jchf.2012.12.004.

22. Louhelainen M, Vahtola E, Kaheinen P, еt al. Effects of levosimendan on cardiac remodeling and cardiomyocyte apoptosis in hypertensive Dahl/Rapp rats. Br. J. Pharmacol. 2007;150(7):851-861. DOI:10.1038/sj.bjp.0707157.

23. Fedorova MV, Petrova EB, Fedorova KV. The effect of levosimendan on patients with a low ejection fraction of the left ventricle during acute decompensation of heart failure. Medicinskij Al'manah. 2016;(4):74-9 (In Russ.) DOI:10.21145/2499-9954-2016-4-74-79.

24. Nieminen MS, Buerke M, Cohen-Solál A, et al. Role of levosimendan in the treatment of acute heart failure complicating the acute coronary syndrome: review and consensus of experts. Int J Cardiol. 2016:1(218):150-7. DOI:10.1016/j.ijcard.2016.05.009.

25. Sonntag S, Sundberg S, Lehtonen LA, Kleber FX. The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. J Am Coll Cardiol. 2004;43(12):2177-82. DOI:10.1016/j.jacc.2004.02.052.

26. Bunte S, Behmenburg F, Bongartz A, et al. Preconditioning by Levosimendan is Mediated by Activation of Mitochondrial Ca2+-Sensitive Potassium (mBKCa) Channels. Cardiovasc Drugs Ther. 2018;32(5):427-34. DOI:10.1007/s10557-018-6819-5.

27. Landoni G, Biondi-Zoccai G, Greco M, et al. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Crit Care Med. 2012;40(2):634-46. DOI:10.1097/CCM.0b013e318232962a.

28. Pölzl G, Allipour Birgani S, Comín-Colet J, et al. Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period. ESC Heart Fail. 2019;6(1):174-81. DOI:10.1002/ehf2.12366.

29. Bouchez S, Fedele F, Giannakoulas G, Gustafsson F, et al. Levosimendan in Acute and Advanced Heart Failure: an Expert Perspective on Posology and Therapeutic Application. Cardiovasc. Drugs Ther. 2018;32(6):617-24. DOI:10.1007/s10557-018-6838-2.

30. Harrison RW, Hasselblad V, Mehta R, et al. Effect of levosimendan on survival and adverse events after cardiac surgery: A Meta-Analysis. Cardiothorac Vasc Anesth. 2013;27(6):1224-32. DOI:10.1053/j.jvca.2013.03.027.

31. Ubasev JuV, Skripkin JuV, Zabelina TS, et al. The positive effect of levosimendan infusion in elderly patients (60-75 years) with a reduced left ventricular ejection fraction (<50%) during the perioperative period in non-cardiac surgery. Vestnik Anesteziologii i Reanimatologii. 2016;(2):29-36 (In Russ.) [ DOI:10.21292/2078-5658-2016-13-2-29-36.

32. Fedorova MV, Kordatov PN, Petrova EB. Preventive use of levosimendan in patients with coronary heart disease with high operational risk. Medicinskij Al'manah. 2015;(3):84-8 (In Russ.) DOI:10.24022/1810-0694-2018-19-4-464-474.

33. Pasyuga VV, Lomivorotov VV, Eremenko AA. Cardiac protective inotropic therapy - opportunities and prospective of using levosimendan in cardiac surgery. Messenger of Anesthesiology and Resuscitation. 2016;13(2):70-7 (In Russ.) DOI:10.21292/2078-5658-2016-13-2-70-77.

34. Ng KT, Chan XL, Tan W, Wang CY. Levosimendan use in patients with preoperative low ejection fraction undergoing cardiac surgery: A systematic review with meta-analysis and trial sequential analysis. J Clin Anesth. 2019;52:37-47. DOI:10.1016/j.jclinane.2018.08.019.

35. Pollesello P, Parissis J, Kivikko M, Harjola V. Levosimendan meta-analyses: Is there a pattern in the effect on mortality? Int J Cardiol. 2016;209:77-83. DOI:10.1016/j.ijcard.2016.02.014.

36. Bhattacharjee S, Soni KD, Maitra S, Baidya DK. Levosimendan does not provide mortality benefit over dobutamine in adult patients with septic shock: A meta-analysis of randomized controlled trials. Thromb Res. 2017;159:76-81. DOI:10.1016/j.jclinane.2017.03.011.

37. Zhou X, Hu C, Xu Z, et al. Effect of levosimendan on clinical outcomes in adult patients undergoing cardiac surgery: a meta-analysis of randomized controlled trials. Interact Cardiovasc Thorac Surg. 2018;26(6):1016-26. DOI:10.1093/icvts/ivy017.

38. Oliva F, Perna E, Marini M, et al. Scheduled intermittent inotropes for Ambulatory Advanced Heart Failure. The RELEVANT-HF multicentre collaboration. Int J Cardiol. 2018;272:255-9. DOI:10.1016/j.ijcard.2018.08.048.

39. Silvetti S, Belletti A, Fontana A, Pollesello P. Rehospitalization after intermittent levosimendan treatment in advanced heart failure patients: a meta-analysis of randomized trials. ESC Heart Fail. 2017;4(4):595-604. DOI:10.1002/ehf2.12177.

40. Ledjahova MV, Nasonova SN, Zhirov IV, et al. The effect of levosimendan on kidney function in the treatment of acute decompensation of heart failure. Rational Pharmacotherapy in Cardiology. 2018;2:176-84 (In Russ.) DOI:10.20996/1819-6446-2018-14-2-176-183.

41. Lannemyr L, Ricksten SE, Rundqvist B, et al. Differential Effects of Levosimendan and Dobutamine on Glomerular Filtration Rate in Patients With Heart Failure and Renal Impairment: A Randomized Double-Blind Controlled Trial. J Am Heart Assoc. 2018;7(16):e008455. DOI:10.1161/JAHA.117.008455.

42. Roehl AB, Zoremba N, Kipp M, Schiefer J. The effects of levosimendan on brain metabolism during initial recovery from global transient ischaemia/hypoxia. BMC Neurol. 2012;12:81. DOI:10.1186/1471-2377-12-81.

43. Roehl AB, Hein M, Loetscher PD, et al. Neuroprotective properties of levosimendan in an in vitro model of traumatic brain injury. BMC Neurol. 2010;10:97. DOI:10.1186/1471-2377-10-97.

44. Hein M, Zoremba N, Bleilevens C, et al. Levosimendan limits reperfusion injury in a rat middle cerebral artery occlusion (MCAO) model. BMC Neurol. 2013;13:106. DOI:10.1186/1471-2377-13-106.

45. Das B, Sarkar C. Pharmacological preconditioning by levosimendan is mediated by inducible nitric oxide synthase and mitochondrial KATP channel activation in the in vivo anesthetized rabbit heart model. Vascul Pharmacol. 2007;47(4):248-56. DOI:10.1016/j.vph.2007.06.008.

46. Katircioglu SF, Seren M, Parlar AI, et al. Levosimendan effect on spinal cord ischemia-reperfusion injury following aortic clamping. J Card Surg. 2008;23(1):44-8. DOI:10.1111/j.1540-8191.2007.00486.x.

47. Wanderer S, Mrosek J, Gessler F, et al. Levosimendan Reduces Prostaglandin F2a-dependent Vasoconstriction in Physiological Vessels and After Experimentally Induced Subarachnoid Hemorrhage. Curr Neurovasc Res. 2018;5(1):72-80. DOI:10.2174/1567202615666180328121025.

48. Konczalla J, Wanderer S, Mrosek J, Gueresir E. Levosimendan, a new therapeutic approach to prevent delayed cerebral vasospasm after subarachnoid hemorrhage? Acta Neurochir (Wien). 2016;158(11):2075-83. DOI:10.1007/s00701-016-2939-5.

49. Onichimowski D, Nosek K, Goraj R. Use of levosimendan in the treatment of cerebral vascular vasospasm: a case study. Drug Des Devel Ther. 2018;12:1777-83. DOI:10.2147/DDDT.S158237.

50. Kundra TS, Nagaraja PS, Bharathi KS, et al. Inhaled levosimendan versus intravenous levosimendan in patients with pulmonary hypertension undergoing mitral valve replacement. Ann Card Anaesth. 2018;21(3):328-32. DOI:10.4103/aca.ACA-19-18


For citations:

Lebedeva N.B., Chesnokova L.Yu. The Use of Levosimendan for the Treatment of Heart Failure and its Potential Organoprotective Effects. Rational Pharmacotherapy in Cardiology. 2022;18(2):218-224. (In Russ.)

Views: 84

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)